Information Provided By: 
Fly News Breaks for February 15, 2019
INSM
Feb 15, 2019 | 08:12 EDT
As previously reported, JMP Securities analyst Liisa Bayko upgraded Insmed to Outperform from Market Perform, stating that her survey of "early adopters" of Arikayce shows a high rate of utilization with a favorable early experience that is encouraging more usage. This suggests Arikayce will beat 2019 consensus, contends Bayko, who raised her 2019 Arikayce revenue estimates. She set a $40 price target on Insmed shares.
News For INSM From the Last 2 Days
There are no results for your query INSM
